J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped

J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.

Oct 18, 2024 - 04:00

J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped

J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.

Read the original article

Tags:

Previous Article

Lexicon partners Viatris for global expansion of sotagliflozin

Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to gover...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

FDA admonishes Jiangsu Hengrui’s manufacturing site fol...

Jun 8, 2024

AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine

AstraZeneca, maker of FluMist, seeks to allow at-home a...

Oct 24, 2023

MSD’s Welireg secures FDA approval for renal cell carcinoma

MSD’s Welireg secures FDA approval for renal cell carci...

Dec 16, 2023